<code id='69EB4B0480'></code><style id='69EB4B0480'></style>
    • <acronym id='69EB4B0480'></acronym>
      <center id='69EB4B0480'><center id='69EB4B0480'><tfoot id='69EB4B0480'></tfoot></center><abbr id='69EB4B0480'><dir id='69EB4B0480'><tfoot id='69EB4B0480'></tfoot><noframes id='69EB4B0480'>

    • <optgroup id='69EB4B0480'><strike id='69EB4B0480'><sup id='69EB4B0480'></sup></strike><code id='69EB4B0480'></code></optgroup>
        1. <b id='69EB4B0480'><label id='69EB4B0480'><select id='69EB4B0480'><dt id='69EB4B0480'><span id='69EB4B0480'></span></dt></select></label></b><u id='69EB4B0480'></u>
          <i id='69EB4B0480'><strike id='69EB4B0480'><tt id='69EB4B0480'><pre id='69EB4B0480'></pre></tt></strike></i>

          explore

          explore

          author:hotspot    Page View:5865
          Adobe

          By some measures, private equity investment lagged in 2023, a year marked by growing distress and high-profile downfalls among private equity-backed health care companies.

          Even so, three sectors still managed to see strong deal flow and prices: med spa, cardiology, and clinical trial sites, according to a new PitchBook report analyzing private equity investments in health care services in 2023. Each of the three niches continue to generate buzz among investors, even as other areas fizzle.

          advertisement

          It’s not that those three industries are perfect fits for private equity, it’s that the more obvious areas like autism therapists and physician practices are struggling with high interest rates and regulatory scrutiny, said Rebecca Springer, PitchBook’s lead health care analyst.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge

          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more
          AI generated plenty of interest at JPM but not a lot of trust
          AI generated plenty of interest at JPM but not a lot of trust

          AdobeYoudidn’tneedmachinelearningtomakeonepredictionabouttheyear’sbiggestconferenceforhealthcareinve

          read more
          Medicare details structure of new drug price negotiation program
          Medicare details structure of new drug price negotiation program

          MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

          read more

          Prior authorization will have to move faster under new Biden rule

          AdobeTheBidenadministrationmovedWednesdaytoforceinsurancecompaniestogivespecificreasonsfordenyingcov